Weight Loss

Eating less and still gaining weight? Doctors explain the hidden reasons

Experts explain how under-eating, skipped meals, hormonal imbalance, stress and metabolic slowdown can push the body into survival mode and make losing weight harder over time

Gene therapy for weight loss: Can one shot replace lifelong GLP-1 drugs?

US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that aims to trigger long-term weight loss by programming the pancreas to produce more GLP-1 hormone

Confused about weight loss? Endocrinologist explains where to start right

Endocrinologist explains how to build a realistic weight-loss plan that can help you lose fat without regaining it

How many eggs a day is safe? Expert answers cholesterol, belly fat questions

Eggs are praised as a protein powerhouse but blamed for cholesterol. A gastroenterologist answers common questions people still ask about weight loss, liver health, and daily egg intake

Weight regain after weight loss drugs is common; here's how to prevent it

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Is liposomal berberine the new weight-loss fix or just online hype?

Promoted as a natural shortcut to fat loss, liposomal berberine is drawing caution from doctors over safety, drug interactions and misleading comparisons with Ozempic

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. A preliminary review in January 2024 showed no link between the drugs and suicidal thought or actions, the FDA said. At that time, however, officials said they could not rule out that a small risk may exist. The new analysis puts those concerns to rest. Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted. Today's FDA action will ensure consistent messaging across the labelling for all FDA-approved GLP-1 RA medications, officials said.

Why weight returns fast after stopping obesity drugs? Homeostasis explained

Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected

Stopping Ozempic or Mounjaro? The weight may come back faster than you think

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

How eggs can help you come off Wegovy, solve problem of weight regain

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

GLP-1 launches inject over 2x rise in weight-loss market sales in 2025

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

The viral 'oatzempic' drink trend: Does this oat blend actually work?

Social media is hailing Oatzempic as a natural way for weight-loss. But does it actually work, and is it safe to rely on?

Five ways to improve your health in 2026 without focusing on weight loss

Many New Year resolutions focus on weight but long-term health is shaped by wider habits and small realistic steps can add up to meaningful health gains over the year

Novo Nordisk secures US FDA approval for first weight-loss pill

US-listed shares of Novo jumped 8 per cent and Lilly fell 1 per cent in extended trading after the approval announcement

Novo gets US nod for Wegovy pill, eyes January launch in obesity market

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

How fatherhood helped Ed Sheeran lose 14 kg and transform his health

Fatherhood, not fame, became the turning point in Ed Sheeran's health journey, prompting gradual lifestyle changes that improved both his physical and mental wellbeing

Mounjaro and the brain: Why cravings fade at first, then return later

A rare brain-recording study found tirzepatide briefly muted activity linked to 'food noise'; months later the signals and intrusive thoughts returned, hinting at limits to its effect

How isabgol improves gut function and supports weight management

Long used for digestion, psyllium husk or isabgol is now being linked to better gut health, appetite control and modest weight loss. Here's how it works and how to use it safely

Ozempic in India: What it does and how it fits into a growing health crisis

From regulating appetite to improving blood sugar control, GLP-1 drugs like Ozempic are emerging as powerful metabolic tools at a time when India urgently needs better solutions

Novo Nordisk launches Ozempic in India at ₹2,200/week amid patent battles

Ozempic debuts in India at ₹2,200 per week, offering a new treatment option for type 2 diabetes as demand grows for effective and easy-to-use metabolic health therapies